This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: D86.3 (Sarcoidosis of skin) | Special Copayment Reduction: V111 (rare disease, 10% copayment for 5 years after registration) |
| B. Synonyms | Cutaneous sarcoidosis, cutaneous granulomatosis, Cutaneous sarcoidosis, Sarcoidosis of skin, lupus pernio, cutaneous Boeck disease, cutaneous sarcoid granulomatosis |
| C. Adult onset | Very likely to first manifest in adulthood — most commonly manifests in adults aged 20–50. Skin involvement in 24.3% of Korean sarcoidosis patients. It is common for a skin lesion to be the first clue to sarcoidosis, leading to diagnosis. The erythema nodosum (Löfgren syndrome) form is especially common in young women. |
| 1. History | 1877 Hutchinson first describes skin nodules → 1899 Boeck names it "benign miliary lupus" (beginning from skin lesions) → 1917 Schaumann establishes the concept of a systemic disease → diagnosis becomes easier with the spread of skin biopsy → in the late 20th century a classification system for various skin phenotypes such as lupus pernio, erythema nodosum, and maculopapules is established. |
| 2. Causes | Causes of cutaneous sarcoidosis: percutaneous exposure or cutaneous spread of systemic sarcoidosis. Skin-limited granulomas may be induced by local antigens (tattoo pigment, foreign bodies, trauma antigens at scar sites). Skin manifestation of a systemic immune response. Genetic susceptibility (HLA-DRB1, etc.) is shared. |
| 3. Genetics | Polygenic inheritance (same as systemic sarcoidosis). Associated with HLA-DRB1. No specific genetic association has been established for skin-only sarcoidosis. Chronic lupus pernio may be associated with HLA-DRB1*1501. |
| 4. General epidemiology | Skin involvement: 25–35% of all sarcoidosis (West), 24.3% (Korea). More common in women and African Americans. Erythema nodosum (nonspecific skin reaction): in acute Löfgren syndrome. Lupus pernio: marker of chronic systemic sarcoidosis. Skin biopsy: easiest and safest method of tissue confirmation. |
| 5. Pathophysiology | CD4+ Th1-mediated non-caseating granuloma formation in the dermis or subcutaneous fat. Local antigens (foreign bodies, tattoos, antigens within scars) or systemic hematogenous antigen spread activate skin APCs → secretion of TNF-α and IFN-γ → epithelioid granuloma formation → characteristic skin lesions. |
| 6. Symptoms | Sarcoid-specific lesions: papules and plaques (face, neck), subcutaneous nodules, lupus pernio (purple plaques on nose and ears). Nonspecific lesions: erythema nodosum (Löfgren syndrome), scar sarcoidosis (granulomas in existing scars). Usually painless. Cosmetic and psychological burden. |
| 7. Signs | Various forms of skin lesions (papules, plaques, nodules, lupus pernio). Histopathology: non-caseating epithelioid granuloma within the dermis (naked granuloma). Markers of systemic sarcoidosis activity: serum ACE, C4, calcium. Evaluation for concurrent systemic involvement is essential. |
| 8. Screening | Dermatology referral and skin biopsy for suspicious skin lesions (easiest screening and confirmation method). Chest X-ray (screening for concurrent lung and lymph node involvement). Serum ACE, calcium. Ophthalmologic examination. IGRA (to exclude tuberculosis). Systemic evaluation: lung function, electrocardiogram. |
| 9. Diagnosis | Skin biopsy (4 mm punch or excisional biopsy) + histopathology (non-caseating epithelioid granuloma + exclusion of tuberculosis and fungi). Chest CT, lung function, and blood tests in parallel to exclude or confirm systemic sarcoidosis. Differential diagnosis: tuberculous skin lesions, fungal skin infection, scar foreign body granuloma, granuloma annulare, Crohn disease skin lesions, other granulomatous skin diseases. |
| 10. Treatment | First line: topical steroids (potent agents, clobetasol) or intralesional steroid injection (triamcinolone). Second line: hydroxychloroquine (oral). Third line: systemic steroids (when cosmetically important or with systemic involvement), methotrexate, tetracyclines. Fourth line: infliximab, adalimumab. Lupus pernio: hydroxychloroquine and systemic steroids. |
| 11. Prognosis | Erythema nodosum (nonspecific reaction): favorable, resolves spontaneously. Sarcoid papules, macules, and plaques: some remit spontaneously, some become chronic. Lupus pernio: chronic course, marker of systemic involvement. Isolated skin lesions (no systemic involvement): relatively favorable. Cosmetic problems such as scarring and pigmentary change persist. |
| 12. Prevention | Minimize exposure to foreign bodies (tattoo pigment, piercings). Sunscreen (some forms are photoaggravated). Regular skin follow-up and systemic evaluation. Drug-induced sarcoid reaction: consider discontinuing the causative drug. Provide psychological support and guidance on cosmetic care. |
| 13. References | Wanat KA, Rosenbach M. Cutaneous sarcoidosis. Clin Chest Med. 2015 … and 9 other papers |
Cutaneous sarcoidosis is the phenotype that was the starting point for the birth of the disease concept of sarcoidosis. In 1877, the British physician Jonathan Hutchinson first described a patient with purple to brown firm nodular skin lesions accompanied by peripheral lymph node enlargement. These skin lesions were later confirmed to correspond to the representative skin phenotype of sarcoidosis named "lupus pernio." Hutchinson's case report left an important clinical insight that a skin lesion can be a clue to a systemic disease.
In 1899, the Norwegian Caesar Boeck, naming small granulomatous skin nodules "benign miliary lupus," was the first to clearly describe the histologic feature that, unlike lupus vulgaris, these lesions form non-caseating granulomas in the skin. He described the form of these lesions as looking like "flesh (sarcoid)," from which the name "sarcoidosis" derives. That is, the very name of the disease sarcoidosis originated from skin lesions.
In the early 20th century, Jörgen Schaumann established the concept of systemic lymphogranulomatosis with skin lesions and emphasized that the skin is one of the organs expressing systemic sarcoidosis. In the late 20th century, the spread of skin biopsy made histologic diagnosis of cutaneous sarcoidosis easier, and various skin lesion types (papules, plaques, subcutaneous nodules, lupus pernio, erythema nodosum, scar sarcoidosis, alopecia sarcoidosis, etc.) were classified and described. In particular, the recognition of lupus pernio as a marker lesion of chronic systemic sarcoidosis was an important clinical advance.
In the 21st century, the value of skin lesions as an indicator reflecting the activity of systemic sarcoidosis is being studied, and sarcoid granulomas induced by foreign body reactions occurring at tattoo sites, previous scar sites, and piercing sites are drawing attention. Drug-induced cutaneous sarcoid reactions from new cancer immunotherapy agents such as immune checkpoint inhibitors (anti-PD-1, anti-CTLA-4) are also increasing, making clinical awareness of cutaneous sarcoidosis all the more important. In Korea, skin involvement has been reported in 24.3% of all sarcoidosis patients, confirmed as the second most common organ involved after the lung (93.5%) (2021, Scientific Reports).
The cause of cutaneous sarcoidosis is understood as a complex multifactorial disease in which skin-specific factors are added on the same basis as systemic sarcoidosis. Among systemic causes, genetic susceptibility (complex inheritance such as HLA-DRB1) and an abnormal Th1 cell-mediated immune response to environmental antigens form the foundation, and this immune response also reaches the skin via the hematogenous route to form granulomas.
Several local triggering factors in the skin have been studied. Exposure to a foreign body is an important local triggering factor. Tattoo pigments (particularly red cinnabar, black carbon pigment, and blue cobalt pigment) can induce a granulomatous reaction in the skin, and cases of sarcoid granulomas developing at tattoo sites in patients with sarcoidosis have been reported. Sarcoid granulomas can also form at piercing sites and within old scars (surgical scars, traumatic scars); this is called scar sarcoidosis, which is a distinctive marker finding of cutaneous sarcoidosis and is strongly associated with the activity of systemic sarcoidosis.
In addition, insect bites, exposure to metals (beryllium, aluminum, zirconium), and silica exposure can also induce a skin granulomatous reaction. These foreign bodies or chemicals promote a local immune response within the dermis, leading in genetically susceptible individuals to a persistent Th1 response and granuloma formation. Drug-induced cutaneous sarcoid reactions are also increasing. Immune checkpoint inhibitors (ipilimumab, nivolumab, pembrolizumab), interferon-alpha (in the treatment of chronic hepatitis), TNF-α inhibitors (paradoxical reaction), and some antiepileptic drugs can induce a skin sarcoid-like granulomatous reaction. In this case lesions often improve after the drug is stopped, but when it occurs during cancer immunotherapy, the decision on whether to continue treatment must be made carefully.
Microbial antigens are also being studied as a cause of cutaneous sarcoidosis. There are reports, mainly from studies in Japan, that Cutibacterium acnes is detected in cutaneous sarcoidosis lesions, suggesting that a resident skin bacterium may act as the antigen source triggering the immune response. However, the causal relationship between microbial antigens and cutaneous sarcoidosis has not yet been fully established.
Cutaneous sarcoidosis has the same polygenic genetic background as systemic sarcoidosis, and no separate causative gene specific to skin involvement has been established. Genetic predisposition contributes to the onset of sarcoidosis but does not by itself determine disease. The concordance rate in monozygotic twins is about 40%, so both genetic and environmental factors are important.
The most important genetic risk factor is HLA-DRB1. The way antigens are presented differs according to the HLA-DRB1 allele, which affects whether sarcoidosis develops and its phenotype (acute/chronic, organ affected). In particular, lupus pernio, the characteristic phenotype of chronic cutaneous sarcoidosis, tends to be associated with the HLA-DRB1*1501 allele, and this allele is also associated with chronic systemic sarcoidosis. In contrast, HLA-DRB1*0301 is associated with acute Löfgren syndrome (erythema nodosum + bilateral hilar lymphadenopathy) and with a subtype with a good prognosis among cutaneous sarcoidosis.
The ANXA11 (annexin A11) R230C variant (rs1049550) is associated with overall sarcoidosis risk, and its specific association with the skin involvement phenotype has not yet been clearly studied. In cutaneous sarcoidosis, there is a hypothesis that TNF-α promoter variants and variants in IL-12 and IL-23 pathway genes may affect the intensity of the local Th1 response, but the evidence is insufficient for use in clinical genetic testing. In terms of epigenetics, there are also early study results that DNA methylation changes are observed in cutaneous sarcoidosis lesions.
Epidemiologic data showing that cutaneous sarcoidosis is more common in certain ethnic groups also suggest a genetic predisposition. In African Americans the incidence of cutaneous sarcoidosis is higher than in those of European descent, and the lupus pernio form is observed more commonly. This is consistent with the high prevalence of sarcoidosis overall in African Americans and suggests a race-specific genetic predisposition that has not been sufficiently elucidated. Genetic research on cutaneous sarcoidosis in Korea is currently limited, and research on East Asian-specific genetic factors is needed in the future.
Skin involvement is one of the most common forms of extrapulmonary organ involvement in sarcoidosis. The frequency of skin involvement in Western sarcoidosis patients is reported as 25–35%, and in a Korean patient cohort study (2021) it was 24.3%, a frequency higher than or similar to that for the lung (93.5%) and eyes (19.9%). That is, about one-quarter of all sarcoidosis patients have skin lesions.
Cutaneous sarcoidosis is slightly more common in women, and chronic skin phenotypes such as lupus pernio appear at a high rate particularly in African American women. The age at onset is concentrated at 20–50 years, as in sarcoidosis overall, and it is not uncommon for a skin lesion to be the first clinical finding of sarcoidosis and for systemic sarcoidosis to be confirmed after dermatology referral. A Brazilian study (2020, PMC7058863) found a distribution among 72 cutaneous sarcoidosis patients of papules and plaques (31.9%), subcutaneous nodules (22.2%), and lupus pernio (18%).
One of the epidemiologic points of importance of cutaneous sarcoidosis is that skin biopsy is the easiest and safest method of tissue confirmation in the diagnosis of systemic sarcoidosis. When there is a skin lesion, granulomatous tissue can be obtained with a simple punch biopsy in dermatology, without thoracic endoscopy or complicated procedures. Therefore, in sarcoidosis patients with skin involvement, skin biopsy is the first choice for diagnosis. Even in patients diagnosed with systemic sarcoidosis, the presence and form of skin lesions provide important clinical information reflecting disease activity and the extent of systemic involvement.
Cutaneous sarcoidosis often follows a relatively benign course, but lupus pernio is associated with chronic systemic sarcoidosis (particularly pulmonary fibrosis and bone sarcoidosis) and is recognized as a marker of a subtype with a poor prognosis. In contrast, the erythema nodosum of Löfgren syndrome is a nonspecific skin reaction of acute sarcoidosis with a good prognosis and resolves spontaneously. Cutaneous sarcoidosis alone (without systemic involvement) is rare, and most cases are accompanied by lung or lymph node involvement.
The pathophysiology of cutaneous sarcoidosis is understood as the granuloma-forming mechanism of systemic sarcoidosis expressed in the skin dermis or subcutaneous tissue. Antigens reaching the skin percutaneously or hematogenously are phagocytosed by skin dendritic cells (including Langerhans cells) and macrophages and presented to CD4+ T cells bound to MHC II molecules. When a Th1-directed cellular immune response is activated in this process, IL-2, IFN-γ, and TNF-α are secreted, causing skin macrophages to differentiate into epithelioid cells and granulomas to form.
The histologic feature of cutaneous sarcoid granulomas is a structure called a "naked granuloma," in which epithelioid macrophages and multinucleated giant cells are densely packed in the center with very few lymphocytes at the periphery. This is a characteristic finding that distinguishes it from the tuberculous granuloma (a "clothed" granuloma made up of central caseous necrosis + surrounding lymphocytes and fibroblasts). Granulomas are distributed through the full thickness of the dermis and the subcutaneous tissue, and depending on distribution, various skin phenotypes appear, ranging from near the epidermis to subcutaneous nodules.
In foreign body-induced cutaneous sarcoidosis, the foreign body (tattoo pigment, piercing metal, foreign material within a scar, etc.) provides continuous antigenic stimulation that maintains the local granulomatous reaction. In scar sarcoidosis in particular, foreign material remaining within an existing scar or damaged collagen fragments may act as antigens. Scar sarcoidosis presents as red, firm raised lesions suddenly appearing in previously asymptomatic scars when systemic sarcoidosis becomes active, and is used as an important clinical indicator of systemic sarcoidosis activity.
In terms of calcium metabolism, overproduction of calcitriol (1,25(OH)2D3) through overexpression of 1α-hydroxylase by activated macrophages can also occur in cutaneous sarcoidosis, which can lead to systemic hypercalcemia and hypercalciuria. However, hypercalcemia with isolated skin involvement is less common than with extensive granulomatous involvement of the lungs or lymph nodes. Ultraviolet (UV) exposure can be an aggravating factor in some cutaneous sarcoidosis, presumably because UV affects the function of skin dendritic cells that regulate the immune response.
The skin lesions of cutaneous sarcoidosis are broadly divided into sarcoid-specific lesions and non-specific reactive lesions. Specific lesions are those in which sarcoid granulomas are histologically confirmed, and non-specific lesions are reactive skin changes occurring in sarcoidosis without granulomas in the tissue.
The most common among the specific lesions are papules and plaques. Brown to purple papules a few mm to several cm in diameter, or plaques without scale, occur on the face (especially around the eyes, nose, and lips), neck, shoulders, and extremities. They are usually painless, and the surface is smooth or has a slightly agave-like texture. When chronic, they may leave pigmentation or scarring. Lupus pernio is the most characteristic lesion of chronic cutaneous sarcoidosis, with purple to violet firm plaques or nodules appearing on the nose, ears, cheeks, and lips. Although the name includes "lupus," it is an entirely different disease from systemic lupus erythematosus (SLE), and it is strongly associated with chronic systemic sarcoidosis (especially pulmonary fibrosis, bone cysts, and salivary gland involvement). Subcutaneous nodules are granulomas in the subcutaneous fat, palpable as painless firm nodules, and occur readily on the extremities.
Among non-specific lesions, erythema nodosum is the most important. Painful red nodules appear on the front of the lower legs, and it is a component of Löfgren syndrome. The histology of erythema nodosum is inflammation of the fat layer (panniculitis) without sarcoid granulomas, a non-specific reaction due to an immune response rather than a sarcoidosis-specific reaction. Scar sarcoidosis is infiltration of sarcoid granulomas occurring within a previous scar, presenting as a scar suddenly becoming red, thickened, and raised, and it is an important marker of activation of systemic sarcoidosis. All skin lesions are usually non-pruritic or only mildly so, and mainly cause cosmetic and psychological burden.
On physical examination, sarcoid skin lesions are observed in a wide variety of forms. Papules are brown to purple dome-shaped elevations a few mm in diameter that are firm on palpation. Plaques are brown to purple broad lesions with ill-defined borders formed by the fusion of several papules. Lupus pernio is a purple to blue-violet firm plaque appearing on the nose, ears, and cheeks, and over time the shape of the nose may become deformed along with pigmentation. Subcutaneous nodules are firm nodules of 1–3 cm palpable beneath the skin, with normal or slightly changed overlying skin color.
The histopathologic findings of the skin biopsy are the key to diagnosis. Non-caseating epithelioid granulomas are distributed through the full thickness of the dermis (from the subepidermal region to the deep dermis), and the "naked granuloma" pattern is characteristic, with epithelioid macrophages and Langhans-type or foreign body-type multinucleated giant cells densely packed in the center and very few lymphocytes at the periphery. Fungi are excluded with PAS stain and Grocott silver stain, and tuberculosis is excluded with AFB staining and Mycobacterium tuberculosis culture. Negative Ziehl-Neelsen and negative fungal culture support the diagnosis of sarcoidosis. The presence of foreign material (silica, tattoo pigment) is checked with polarized light microscopy.
After skin lesions are confirmed, blood tests to assess systemic activity (ACE, sIL-2R, calcium), a complete blood count, liver and kidney function tests, chest X-ray, pulmonary function tests, and an ophthalmologic examination must be performed. Because most patients with cutaneous sarcoidosis also have systemic involvement, it is inappropriate to focus only on skin treatment without a systemic evaluation. PET-CT can be used to identify sites of active whole-body involvement and determine sites needing biopsy.
Screening for cutaneous sarcoidosis begins with clinical suspicion. Sarcoidosis should be included in the differential diagnosis when unexplained brown to purple painless papules, macules, or plaques are persistently present on the face, neck, or extremities, or when a red, firm lesion suddenly develops in an existing scar or tattoo site. The Löfgren syndrome pattern of erythema nodosum + arthralgia + fever should also immediately raise suspicion of sarcoidosis.
After dermatology referral, skin biopsy is performed. Sufficient tissue extending to dermal depth is obtained with a 4 mm punch biopsy or excisional biopsy. Because skin biopsy is a minimally invasive method that allows tissue to be obtained simply, without bronchoscopy or mediastinal surgery, skin biopsy is performed first as the primary diagnostic method when there is a skin lesion. Biopsy tissue undergoes H&E staining, AFB staining, Grocott staining, and polarized light microscopy.
If sarcoid granulomas are confirmed after skin biopsy, additional tests are performed to assess systemic involvement: chest X-ray, chest HRCT (if needed), pulmonary function tests, serum ACE, sIL-2R, and calcium, complete blood count, liver and kidney function tests, IGRA (to exclude tuberculosis), ophthalmologic examination (uveitis), and electrocardiogram. Through this comprehensive evaluation, it is judged whether the skin lesion is part of systemic sarcoidosis or a local sarcoid reaction, and the need for systemic treatment is decided.
Cutaneous sarcoidosis is confirmed by histologic confirmation of non-caseating epithelioid granuloma on skin biopsy and exclusion of infectious granulomatous diseases such as tuberculosis and fungal infection. The diagnostic criteria are: (1) compatible clinical findings (characteristic skin lesions), (2) non-caseating granuloma with a naked granuloma pattern on histopathology, and (3) negative AFB staining and culture and negative fungal staining and culture.
The differential diagnosis includes various granulomatous skin diseases. Granuloma annulare, unlike sarcoidosis, appears mainly on the backs of the hands in a ring shape and is characterized by mucin deposition in the tissue. Tuberculous skin lesions are differentiated by AFB staining and Mycobacterium tuberculosis culture. Fungal skin infections (sporotrichosis, chromoblastomycosis, etc.) are excluded with special fungal stains and culture. Foreign body granuloma shows foreign material under polarized light microscopy, but foreign material can also be present in sarcoidosis. Crohn disease skin lesions are evaluated together with a history of gastrointestinal involvement. Drug-induced granuloma is confirmed by improvement after the causative drug is stopped.
In special situations, lupus pernio may be clinically confused with the skin lesions of systemic lupus erythematosus (SLE), but SLE is distinguished by malar rash, positive antinuclear antibody (ANA), and decreased C3 and C4. Scar sarcoidosis needs to be differentiated from hypertrophic scars or keloids, and histologic confirmation of granulomas is the key to differentiation. Tattoo-associated sarcoidosis is a granulomatous reaction occurring at the tattoo site, and polarized light microscopy and evaluation for systemic sarcoidosis are performed together to differentiate it from foreign body granuloma.
Treatment of cutaneous sarcoidosis is determined by the location and size of the lesion, its cosmetic impact, the presence of concurrent systemic involvement, and symptoms. Mild lesions with skin-only involvement and little cosmetic burden can be observed without specific treatment, but lesions in cosmetically important areas such as the face have an important effect on the patient's quality of life, so treatment is considered.
First-line treatment is topical corticosteroids. A potent topical steroid (Class I–II, clobetasol propionate 0.05% cream or ointment) is applied 1–2 times a day for 4–8 weeks. Intralesional triamcinolone acetonide injection (5–10 mg/mL, 0.1–0.5 mL per lesion) is particularly effective for thick, firm plaques and lupus pernio. Topical tacrolimus ointment can also be used as an alternative to steroids for facial lesions. For cosmetic management, laser treatment (Nd:YAG laser, pulsed dye laser) has also been tried for lupus pernio.
As second-line treatment, oral hydroxychloroquine (200–400 mg per day) is effective for cutaneous sarcoidosis, especially the papule and plaque forms, and has fewer side effects than systemic steroids. Tetracyclines (minocycline 100 mg/day, doxycycline 100 mg/day) have also been reported effective for cutaneous sarcoidosis and have anti-inflammatory and anti-granulomatous effects. When systemic involvement is present, oral prednisolone (0.3–0.5 mg/kg/day) is started.
In refractory cutaneous sarcoidosis, immunosuppressants such as methotrexate and azathioprine are added, or biologics (infliximab, adalimumab) are used as third- or fourth-line treatment. In particular, cases have been reported in which infliximab produced marked lesion improvement in lupus pernio. Drug-induced cutaneous sarcoidosis often improves when the causative drug is stopped, but when it occurs during cancer immunotherapy, the decision on whether to continue treatment must be made in consultation with the oncology medical team.
The prognosis of cutaneous sarcoidosis varies with the lesion type, the presence of concurrent systemic involvement, and treatment response. Erythema nodosum (non-specific reactive) resolves spontaneously within several weeks to months and has a very good prognosis. Erythema nodosum occurring as part of Löfgren syndrome resolves with spontaneous remission of systemic sarcoidosis. Papules and plaques remit spontaneously in some and become chronic in others, persisting for years or leaving scarring and pigmentation. They improve if they respond to treatment, but recurrence is common.
Lupus pernio is the cutaneous sarcoidosis type with the poorest prognosis and is strongly associated with chronic systemic sarcoidosis (pulmonary fibrosis, bone cysts, renal involvement, etc.). The response to treatment is limited and recurrence is common. Patients with lupus pernio should be followed regularly for the extent and activity of systemic involvement. Cosmetic problems such as deformity of the nose affect quality of life in the long term. Subcutaneous nodules resolve spontaneously in some but tend to become chronic. Scar sarcoidosis is associated with the activity of systemic sarcoidosis and so may respond to systemic treatment.
Patients with cutaneous sarcoidosis alone (without systemic involvement) have a better overall prognosis than patients with concurrent systemic involvement. However, systemic involvement cannot be completely excluded on the basis of skin lesions alone, so regular follow-up is needed. Psychosocially, facial lesions can cause anxiety about appearance, depression, and withdrawal from social activities, and psychological support and linkage to specialized dermatologic treatment are important for improving quality of life.
No prevention specific to cutaneous sarcoidosis has been established. Avoiding known triggering factors is a practical preventive strategy. Because tattoo pigments (especially red cinnabar and blue cobalt types) can induce a foreign body reaction in the skin and trigger granulomas in people predisposed to sarcoidosis, patients with sarcoidosis are advised to avoid tattoos. Piercing likewise increases exposure to foreign material in the skin, so caution is needed.
Because ultraviolet (UV) exposure can be an aggravating factor in some cutaneous sarcoidosis lesions, routine use of sunscreen is recommended. Minimizing occupational exposure to organic and inorganic dust also falls under prevention of sarcoidosis overall and applies to cutaneous sarcoidosis. For drug-induced cutaneous sarcoid reactions, when starting the causative drug (immune checkpoint inhibitors, interferon, etc.), early detection through regular dermatology examinations is advised, and when symptoms occur, the decision on whether to continue the drug is made in consultation with oncology and immunology.
For follow-up management after diagnosis, regular dermatology follow-up (at 3–6 month intervals) and systemic evaluation (chest X-ray, lung function, ophthalmologic examination) are used to monitor lesion progression and the occurrence of systemic involvement. During long-term use of topical steroids, watch for side effects such as skin atrophy and telangiectasia, and when systemic steroids are used, standard measures to prevent side effects are implemented. Psychological support and guidance on cosmetic care (colored makeup, camouflage cream, etc.) help quality of life. Guidance on the domestic rare disease support system (Special Copayment Reduction V111) and connection to patient support groups are actively provided.